Drug Profile
Ivacaftor/tezacaftor - Vertex Pharmaceuticals
Alternative Names: IVA/TEZ; ivacaftor/Tezacaftor+ivacaftor-copackaged; Ivacaftor/VX 661; PrSYMDEKO; SYMDEKO; SYMDEKO(Copackaged); Symkevi; TEZ/IVA; Tezacaftor/ivacaftor; VX-661/ivacaftor; VX-661/VX-770; VX-770/VX-661Latest Information Update: 20 Nov 2023
Price :
$50
*
At a glance
- Originator Cystic Fibrosis Foundation Therapeutics; Vertex Pharmaceuticals
- Developer Vertex Pharmaceuticals
- Class Amides; Aminophenols; Antifibrotics; Cyclopropanes; Fluorobenzenes; Quinolones; Small molecules
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Cystic fibrosis
Most Recent Events
- 05 Dec 2022 Vertex Pharmaceuticals completes a phase III trial in Cystic Fibrosis (In adults, In adolescents, In children, In the elderly, Combination therapy) in the US, Australia, Belgium, Canada, Denmark, France, Germany, Ireland, Israel, Italy, Netherlands, Spain, Sweden and the UK (PO,Tablet) (NCT02565914)
- 09 Mar 2022 Vertex Pharmaceuticals has patent protection for ivacaftor/tezacaftor in USA and European Union
- 28 Jun 2021 Launched for Cystic fibrosis (In adolescents, In the elderly, In adults) in France (PO)